Quintiles has reported an expanded partnership with Jakarta-based Prodia Clinical Laboratory, through its sister company Prodia the CRO, to facilitate rapid testing of samples from patients in clinical trials in Indonesia. This will allow Quintiles’ biopharmaceutical customers to conduct clinical research in Indonesia and help establish the potential benefits of new medicines in the Indonesian population while contributing to global programs.
Under the agreement, Prodia will provide Quintiles with exclusive access to Prodia’s harmonized central laboratory for a two-year period.
“This agreement demonstrates Quintiles’ commitment to improving human health by increasing participating in global clinical research,” said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines. “Major health issues in Indonesia’s ethnically diverse population of 240 million include infectious and non-communicable diseases, with tobacco-related illnesses also on the rise."
“As the local market leader in laboratory services, Prodia is delighted to partner with Quintiles to help establish Indonesia as a true center of excellence for delivery of clinical trials. We look forward to working with Quintiles and its global biopharma customers to develop novel therapies," said Gunawan Prawiro Suharto, president of Prodia the CRO.